Omiganan

Drug Profile

Omiganan

Alternative Names: 1% Omiganan gel; CLS-001; CPI-226; MBI-226; MBI-594AN; MX 294AN; MX-226; MX-594AN; Omiganan pentachloride - BioWest; Omiganan pentahydrochloride; Omiganan pentahydrochloride 1% gel; Omigard

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator MIGENIX
  • Developer Cadence Pharmaceuticals; Carrus Capital Corporation; Cutanea Life Sciences
  • Class Antibacterials; Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Catheter infections
  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Phase III Rosacea
  • Phase II Acne vulgaris; Atopic dermatitis; Genital warts; Inflammation; Vulvar intraepithelial neoplasia
  • Discontinued Catheter infections

Most Recent Events

  • 21 Dec 2016 Phase-II clinical trials in Inflammation (Combination therapy, In volunteers) in Netherlands (Topical) (EudraCT2016-004702-34)
  • 21 Dec 2016 Cutanea Life Sciences initiates a phase II trial for Skin inflammation (Monotherapy, In volunteers) in Netherlands (Topical) (EudraCT2016-004702-34)
  • 15 Dec 2016 Phase-II clinical trials in Atopic dermatitis (Monotherapy) in Netherlands (Topical) (EudraCT2016-003849-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top